108 results about "Diabetes Mellitus Complications" patented technology

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action.That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, is effective for preventing or treating diabetes mellitus and diabetic complications, and is represented by the formula (I); (wherein R1 represents e.g. an amino group which may be substituted with an alkyl group; R2 represents e.g. hydrogen atom, an alkyl group, a cycloalkyl group or an alkyl group, alkenyl group or alkynyl group which may be substituted with hydrox etc.; R3 represents e.g. an optionally substituted alkyl group, alkenyl group, alkynyl group, aryl group, heteroaryl group, pyridinone group, pyrimidinone group or piperadinone group; Ar represents e.g. an optionally substituted aryl or heteroaryl group; and Q and W are the same as or different from each other and each represents N or CH), a pharmacologically acceptable salt or hydrates thereof.

The present invention relates to a new-type hypoglycemic medicine composition. Said new-type hypoglycemic medicine composition contains biguanide hypoglycemic medicine or its medicinal salt with effective dose, thiazolidione hypoglycemic medicine or its medicinal salt with effective dose, vitamins B with effective dose and medicinal carrier or excipient. Said invention also provides the application of said medicine composition in preparation of medicine for preventing and / or curing diabetes and its complication.

A method for enhancing glycemic control and / or insulin sensitivity in a human subject having diabetic nephropathy and / or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and / or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and / or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Compounds of formula (I)its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates can be used to prevent or treat diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes caused by insulin resistance or impaired glucose tolerance. The compounds can also be used to reduce cholesterol, body weight, blood glucose, triglycerides and free fatty acids in the blood.

The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins.

The invention relates to a traditional Chinese medicine for treating diabetes mellitus and a preparation method thereof. The technical scheme is as follows: the traditional Chinese medicine comprisesthe following raw medical materials: astragali semen, trichosanthes, agrimony, scouring rush, astragalus, rhizoma coptidis, yam, schisandra chinensis, purslane, achyranthes aspera, azolla, salvia, gegen, white peony roots, anemarrhena, fleece-flower roots, gypsum, dodders, buntal, rehmanniae, hen egg yolk, ball cactus and silkworm chrysalis. The preparation method comprises the following steps: taking the raw medical materials by weight portions; grinding and mixing the silkworm chrysalis with the ground hen egg yolk; adding liquor; heating, refluxing, cooling and soaking to prepare medical liquid A; taking the astragalus and the rhizoma coptidis; adding liquor; heating, refluxing, cooling, pulping and soaking to prepare medical liquid B; soaking and pulping the other medical materials inthe liquor; additionally adding liquor to soak and prepare medical liquid C; and mixing the medical liquid A, the medical liquid B and the medical liquid C. The invention has the functions of nourishing yin, clearing heat, activating blood and warming yang, treats both principal and secondary aspects of the disease, not only has favorable treatment effect for the diabetes mellitus, but also has obvious treatment effect on diabetes mellitus complications.

The invention relates to a newly-developed medicine compound for diabetes which contains sulfonylureas drug for diabetes or a bioactive metabolite of the sulfonylureas drug for diabetes or pharmaceutical salt of the sulfonylureas drug for diabetes, and thiazolidinedione drug for diabetes or pharmaceutical salt and vitamin B of the thiazolidinedione drug for diabetes. The compound contains the sulfonylureas drug for diabetes of therapy dose or the bioactive metabolite of the sulfonylureas drug for diabetes or the pharmaceutical salt of the sulfonylureas drug for diabetes, the thiazolidinedione drug for diabetes of therapy dose or the pharmaceutical salt and therapy dose of vitamin B of the thiazolidinedione drug for diabetes or compound which is related to the thiazolidinedione drug for diabetes and has similar bioactivity and pharmaceutical carrier or excipient. The invention also relates to the purpose of the compound in preparation of drug for treating diabetes or preventing diabetes complication, belonging to the pharmaceutical field.

The invention discloses a marine organism type enteral nutrition preparation for diabetes patients, a preparation method of the marine organism type enteral nutrition preparation and application. The nutrition preparation includes, by weight, from 3 to 15 parts of algal polysaccharides, from 1 to 5 parts of marine edible animal protein peptide powder, from 3 to 5 parts of microalgae oil, from 0.3to 2 parts of spirulina powder, from0.1 to 1 part of taurine, from 40 to 45 parts of balsam pear polysaccharide or pumpkin polysaccharide, from 10 to 15 parts of soybean protein isolate powder, from 7 to 10 parts of medium chain triglyceride, from 3 to 8 parts of konjac dietary fibers, from 1 to 5 parts of fruit and vegetable powder, from 0.1 to 0.5 part of wheat bran, from 0.1 to 0.5 part of alpha-lipoic acid and a trace of trace element additives. Marine active functional matters with unique pharmacologic bioactivity are reasonably compounded according to needs of nutrition and metabolism of the diabetes patients, and the personal enteral nutrition preparation for the diabetes patients is developed, provides balanced nutrition for the diabetes patients and former diabetes patients, effectively relieves malnutrition, prevents diabetes, assists in regulating blood sugar level, can effectively prevent diabetes complications, and is favorable for increasing the quality of life of the patients and promoting rehabilitation.

The invention provides a health-care food with functions of enhancing the immunity and assisting to reduce the blood sugar and a preparation method of the food. The health-care food is prepared by mixing the following components in parts by weight: of extract powder and 5-15 parts of cordyceps sinensis zymophyte powder, wherein the extract powder is prepared from 5-13 parts of astragalus membranaceus, 1-10 parts of rhizoma polygonati, and 1-10 parts of medlar through water extraction and concentration. The preparation method comprises the following steps: mixing the astragalus membranaceus, the rhizoma polygonati and the medlar; adding water, immersing and boiling; concentrating an extracting solution to prepare the extract powder; mixing the extract powder with the cordyceps sinensis zymophyte powder to obtain an active component provided by the invention. The health-care food provided by the invention has the double functions of enhancing the immunity and assisting to reduce the blood sugar. After diabetes mellitus patients take the health-care food for a long time, the blood sugar is controlled effectively and the immunity of an organism can be improved; the capability of resisting other diseases, particularly diabetes mellitus complications, of the organism is enhanced.

The invention discloses a pharmaceutical composition for treating diabetes and controlling diabetic complications and application thereof in pharmaceutics, belonging to the technical field of medicines. The pharmaceutical composition provided in the invention comprises a chemical medicine and a Chinese herbal medicine extract, and specifically comprises metformin hydrochloride and cinnamon extract. The pharmaceutical composition in the invention has a good effect on treating diabetes, can effectively control occurrence of diabetic complications, produces low adverse reaction; the utilization of the pharmaceutical composition is more safe and reliable compared to single utilization of chemical medicines and enables usage amount of metformin hydrochloride to be reduced.

The invention relates to the field of medicines and in particular relates to a silkworm pupa polypeptide 2 which can be used for preventing or treating diabetes mellitus. The sequence of the polypeptide 2 is PYERQADEPETKVTKKI. A preparation method of the polypeptide 2 comprises the following steps: (1) decoction; (2) enzymolysis; (3) protein separation; (4) separation and purification through semipreparative RP-HPLC (reverse phase high-performance liquid chromatography); (5) freeze-drying, wherein neutral protease and compound protease are adopted for enzymolysis; macroporous resin and sephadex are adopted for protein separation. The invention provides the application of the polypeptide 2 to treatment of diabetes mellitus and complications of diabetes mellitus, wherein the complications of diabetes mellitus include diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neuropathy. The silkworm pupa polypeptide 2 is extracted from silkworm pupae, has good safety and can be used for effectively preventing or treating diabetes mellitus.

The invention discloses lutein xylitol nutritious drink and a preparation method thereof. The lutein xylitol nutritious drink comprises, by volume of 1000ml, concentrated apple juice 5-20g, citric acid 1.5-2.0g, xylitol mother solution 150-200g, sodium citrate 0.1-0.5g, color retention agent 0.1-0.5g, potassium sorbate 0.3-0.5g, water-soluble xanthophylls 0.5-1.5g with 5% of mass percentage content, taurine 0.1-0.5g, pineapple opacifying essence 0.3-0.7ml, ethyl maltol 1-5mg, xanthan gum 0.4-0.8g, cane sugar SE 110.5-1g and the balance purified water. Drugs and food are used as raw materials,the liquid xylitol is used as sweetener, and the citric acid and the sodium citrate are used as sour agents to perform taste deployment. The lutein xylitol nutritious drink is proper in sour and sweet and comfortable and fresh in taste. Simultaneously, the raw materials are deployed flexibly, nutritional value are high, the purposes of delicious taste and low sugar degree are achieved, the luteinxylitol nutritious drink has the effects of reducing eyestrain, relieving cataract and reducing diabetes mellitus side effects, and diabetic patients can drink relievedly.

This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and / or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and / or diabetic macroangiopathy.

A medical application of general cactus flavone in preparing the natural medicine or health-care food acting to suppress aldose reductase for preventing and treating the complication of diabetes suchas the healing defect of corneal injury, cataract, neuropathy, retinopathy and renal disfunction. The said general cactus flavone is prepared by the solvent extraction method or resin adsorption method and conventional drying method.

A medicinal composition used for preparing the medicines to prevent and treat hyperglycemia, diabetes, and their complications contains insulin sensitizer and B-family vitamins.

The invention discloses a traditional Chinese medicine composition for treating type-2 diabetes. The traditional Chinese medicine composition is composed of the following raw materials: wild discolorcinquefoil herb, wild lalang grass rhizome, wild lygodium japonicum root, ginseng leaves (7 years or above), wild pogonatherum crinitum, wild vitex negundo, winter mulberry leaves green tea, wild agaric, corn stigma and dandelion root. The traditional Chinese medicine composition disclosed by the invention is applicable to patients with the type-2 diabetes and complications of the type-2 diabetes,is free of adverse reactions and is stable in curative effect.

The invention discloses a medicine composition for treating diabetes mellitus and complications thereof, and in particular relates to a medicine composition comprising arctigenin and rosiglitazone or pharmaceutically acceptable salts thereof, and application of the composition in preparation of a medicine for treating diabetes mellitus, diabetes mellitus complications and diseases relative to thediabetes mellitus.

The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and / or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and / or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction, obesity and the like.

The invention provides medical use of a panoxadiol saponin Rb component in the prevention and treatment of diabetic complications and metabolic disorders. A drug is prepared from the panoxadiol saponin Rb component as a single active component or the panoxadiol saponin Rb component and other active compounds, the Rb component mainly contains 50%-98% of five panoxadiol saponins (Rb1, Rb2, Rb3, Rc and Rd), and the other active components include a substance capable of reducing blood glucose level, a traditional Chinese medicine active substance, a natural product, an artificially synthesized compound and an in-vivo active substance. By utilizing independent blood glucose level as an action mechanism, the diabetic metabolic disorders are corrected, the mitochondrial function and oxidation-reduction balance capacity of a diabetic patient can be enhanced, relevant pathological symptoms of mitochondria damage and metabolic disorders caused by pathological factors except diabetes mellitus are resisted, and diseases and pathological symptoms with the metabolic disorders, particularly the mitochondrial functional disorders are prevented and treated. The drug is safe and effective.

The present invention provides pyrazole derivatives represented by the general formula:wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups:and the other represents —(CH2)n—Ar wherein Ar represents an optionally substituted C6-10 aryl group or an optionally substituted C1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C3-8 cycloalkyl group, an optionally substituted C6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5-anhydroglucitol / fructose / mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

The invention relates to an eye health care product capable of preventing and delaying senile macular degeneration and a manufacture method. The eye health care product comprises ingredients by weight by part: 20 parts to 30 parts of chlorella extractives, 10 parts to 25 parts of kiwi fruit extractives, 15 parts to 20 parts of oyster extractives, 20 parts to 25 parts of pine bark extractives, 15 parts to 10 parts of kudzu vine root extractives and 10 parts to 15 parts of whinberry extractives. Compared with the prior art, the eye health care product capable of preventing and delaying senile macular degeneration has the advantages of effectively improving visual function, being accurate in effect and mechanism on health care function of visual function compared with other products sold in markets, and having excellent effects on preventing and curing other macular degeneration, diabetes mellitus complication fundus lesion and cataract.

The invention relates to the field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and decoction for treating diabetes as well as a preparation method and an application. The traditional Chinese medicine composition provided by the invention comprises the following raw materials in parts by mass: 20-30 parts of radix astragali seu hedysari,20-30 parts of radix codonopsis, 40-60 parts of rhizoma polygonati, 20-30 parts of fructus lycii, 20-30 parts of fructus ligustri lucidi, 30-50 parts of rhizoma polygonati odorati and 20-30 parts ofradix angelicae sinensis. The traditional Chinese medicine composition provided by the invention has the effects of reducing blood sugar and improving diabetes complications.

The invention discloses a traditional Chinese medicinal composition for treating diabetes mellitus and a preparation method of the traditional Chinese medicinal composition, and belongs to the technical field of traditional Chinese medicines. The invention aims at providing the traditional Chinese medicinal composition for treating the diabetes mellitus, which is rapid to take effects, short in treatment course, good in therapeutic effect, low in toxic and side effects and not easy for recurrence, as well as the preparation method of the traditional Chinese medicinal composition. The traditional Chinese medicinal composition consists of 29 traditional Chinese medicines, namely radix et rhizoma rhei, radix glycyrrhizae preparata, radix scutellariae, radix rehmanniae preparata, rhizoma dioscoreae, radix adenophorae, rhizoma coptidis, rhizoma anemarrhenae, radix ophiopogonis, rhizoma polygonati, fruits of Chinese wolfberry, radix polygonati officinalis, rhizoma atractylodis, cortex phellodendri, fruits of Chinese magnoliavine, radix codonopsis, radix puerariae, radix trichosanthis, raw radix astragali, herba potentillae discoloris, herba paederiae, semen sojae praeparatum, hirudo, radix notoginseng, seeds of acanthopanax senticosus, stem of dendrobium officinale, winged euonymus twig, herb of Apocynum venetum L. and folium ginkgo. The traditional Chinese medicinal composition has the advantages of being short in treatment course, free from toxic and side effects and not easy for recurrence; the traditional Chinese medicinal composition has a good therapeutic effect on primary diabetes mellitus, secondary diabetes mellitus and diabetes mellitus complications; and the effective rate of the traditional Chinese medicinal composition reaches 90% or above.

The invention provides a composition for adjuvant therapy of hypertension and diabetes. The composition consists of 40-60 parts of potassium chloride, 80-120 parts of lecithin, 240-360 parts of saccharides and 2.4-3.6 parts of magnesium chloride, and the composition can further consist of 24-36 parts of metformin. The invention also provides a preparation which is prepared from the composition, wherein the preparation is in the form of chewing gum, sublingual tablets or hard candies. The composition for the adjuvant therapy of the hypertension and the diabetes provided by the invention can regulate the metabolism of in-vivo potassium ions, so as to treat diabetes complications caused by potassium metabolism imbalance, and simultaneously to keep an in-vivo environment stable; in addition, the composition, which is prepared from a few varieties of raw materials, is low in side effects, and the purpose that various active ingredients supplement each other to develop a synergistic curative effect can be achieved; the preparation, which is prepared into the form of the chewing gum, the sublingual tablets or the hard candies, is more convenient to take and carry, and the preparation, when chewed or kept under a tongue, can stimulate the secretion of saliva, so as to bring benefits for the full absorption of the active ingredients, and in addition, the curative effect of the composition can be fully developed.

The invention belongs to the field of traditional Chinese medicines and in particular discloses a health medicament for treating type 2 diabetes mellitus. The health medicament is prepared from the following active components in parts by weight: mulberry leaves, rhizome of peltate yam, black sesames, radix puerariae, rhizoma atractylodis, negundo chastetree leaves, tortoise plastrons, Chinese caterpillar fungi, cherokee rose fruits, turtle shells, American ginseng, mythic fungi, pilose antlers and pinellia tuberifera. The health medicament is remarkable and durable in curative effect, is capable of effectively lowering blood glucose, maintaining balance of blood glucose level and effectively preventing and controlling diabetes mellitus and diabetes mellitus complications.

The invention belongs to the technical field of biology, and specifically relates to a combined drug for treating diabetes mellitus and complications and a pharmaceutical composition of the combined drug. The invention discloses combined use of components (i): a compound represented by a general formula (I), pharmaceutical salt of the compound and isomers of the compound and the pharmaceutical salt and a component (ii): an SGLT2 inhibitor in preparation of drugs for preventing and / or treating the diabetes mellitus and / or the complications of the diabetes mellitus, and further discloses the pharmaceutical composition containing the components (i) and the component (ii). The combined drug is capable of synergetically reducing blood sugar of db / db diabetic mice, generating an unexpected synergetic effect, improving blood lipid indexes, particularly improving content of triglyceride in serum and further generating a combined effect in aspects of control of body weight and protection of blood lipid, blood pressure, livers and kidneys, so that more benefits are brought to prevention and / or treatment of the diabetes mellitus and the complications including cardiovascular and cerebrovascular diseases, kidney diseases and hepatic diseases.

The invention relates to a pyrazine compound, a stereoisomer, a tautomer and a pharmaceutically acceptable salt thereof, wherein the pyrazine compound, the stereoisomer, the tautomer and the pharmaceutically acceptable salt thereof can treat Alzheimer's disease, Parkinson's disease, Huntington's disease, frontal temporal dementia (FTD), vascular dementia, HIV-related dementia, multiple sclerosis,progressive spinal cord lateral sclerosis, Friedel-Crafts ataxia, neuropathic pain or glaucoma and other neurodegenerative diseases, diabetes mellitus and related diabetic complications, inflammations, oxidative damage and mitochondria-related diseases.

The present invention relates to one composition of gensenoside Rg1 and ferulic acid for preventing and treating cardiac and cerebral vascular diseases and diabetes and its application. The composition consists of gensenoside Rg1 in 5-95 wt% and ferulic acid in 5-95 wt%. Through the synergistic function of gensenoside Rg1 and ferulic acid, the composition can regulate blood functions and treat diseases and disfunction caused by the change in blood system, cardiac and cerebral vascular system or blood sugar. The composition may be further prepared into medicine or food preparation by adding proper amount of supplementary material. The composition has high comprehensive treating effect.